Translator Disclaimer
7 December 2006 Lasers for the treatment of psoriasis
Author Affiliations +
Proceedings Volume 5973, Current Research on Laser Use in Oncology: 2000-2004; 597313 (2006) https://doi.org/10.1117/12.640225
Event: Current Research on Laser Use in Oncology: 2000-2004, 2004, Moscow, Russian Federation
Abstract
Psoriasis is a chronic, genetically-determined disease, characterized by an immuno-mediated pathogenesis. Treatment of psoriasis is often complicated and remains a challenge. Along with the many new immunomodulatory approaches, various laser systems have been employed for chronic plaque psoriasis treatment. Recently, it has been demonstrated that the light produced by xenon-chloride excimers (generated by sophisticated devices with peak emission of 308 nm) is effective in the treatment of several psoriasis forms. We treated patients, ranging in age from 35 to 55 years, affected by plaque-type psoriasis vulgaris with monochromatic excimer light (MEL). We used MEL in a complex with basic treatment. Therapy was administered three times a week. At the end of the 3th week of treatment all patients showed an improvement, as evidenced by flattening of plaques, decreased scaling and erythema, and decreased vesicle and pustule formation. Unwanted side effects such as pain, blistering was not observed. Minimal erythema and a hyperpigmentation were noted in some patients. It was concluded that the MEL therapy may be a valuable option for treatment of plaque-type psoriasis vulgaris in shorter time compare with traditional NB UVB, with exposure to lower cumulative doses
© (2006) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
A. Piruzian, I. Korsunskaya, I. Goldenkova, A. Hertsen, M. Sarkisova, and L. Egorenkova "Lasers for the treatment of psoriasis", Proc. SPIE 5973, Current Research on Laser Use in Oncology: 2000-2004, 597313 (7 December 2006); doi: 10.1117/12.640225; https://doi.org/10.1117/12.640225
PROCEEDINGS
6 PAGES


SHARE
Advertisement
Advertisement
Back to Top